New Legislation
For what now seems like several years, the attention of many institutions and individuals in the European Union Member States with an interest in animal experimentation, has been focused on the replacement of Directive 86/609/EEC on the protection of animals used for experimental and other scientific purposes, 1 as requested by the European Parliament in 2002. After much consultation and discussion within the European Comm ission, the European Parliament and the Member States, Directive 2010/63/EU of the European Parliament and of the Council on the protection of animals used for scientific purposes 2 was approved on 22 September 2010, and the Member States were given until the beginning of 2013 to adapt their own legislation to comply with its requirements.
The preamble to Directive 2010/63/EU is a remarkable statement of hopes and intentions, some of which need to be summarised here. For example, It is necessary to improve the welfare of animals used in scientific procedures by raising the minimum standards for their protection in line with the latest scientific developments [6] ; This Directive represents an important step towards achieving the final goal of full replacement of procedures on live animals for scientific and educational purposes as soon as it is scientifically possible to do so. To that end, it seeks to facilitate and promote the advancement of alternative approaches [10] ; The principles of replacement, reduction and refinement should be considered systematically when implementing this Directive. When choosing methods, the principles of replacement, reduction and refinement should be implemented through a strict hierarchy of the requirement to use alternative methods [11] ; Animals have an intrinsic value which must be respected. There are also the ethical concerns of the general public as regards the use of animals in procedures [12] ; The choice of methods should ensure the selection of the method that is able to provide the most satisfactory results and is likely to cause the minimum pain, suffering or distress. The methods selected should use the minimum number of animals that would provide reliable results and require the use of species with the lowest capacity to experience pain, suffering, distress or lasting harm that are optimal for extrapolation into target species [13] ; There should be an upper limit of pain, suffering and distress above which animals should not be subjected in scientific procedures. To that end, the performance of procedures that result in severe pain, suffering or distress, which is likely to be long-lasting and cannot be ameliorated, should be prohibited [23] ; When developing a common format for reporting purposes, the actual severity of the pain, suffering, distress or lasting harm experienced by the animal should be taken into account rather than the predicted severity at the time of the project evaluation [24] ; and It is also essential, both on moral and scientific grounds, to ensure that each use of an animal is carefully evaluated as to the scientific or educational validity, usefulness and relevance of the expected result of that use. The likely harm to the animal should be balanced against the expected benefits of the project [39] .
In the UK, the Home Office organised a series of public consultations and meetings with stakeholders, on proposals concerning the new Directive, on the provisions of the Directive itself, and on detailed proposals for the transposition of the requirements of the Directive by making amendments to the Animals (Scientific Procedures) Act 1986. 3 This process culminated in debates, in the House of Commons on 3 December 2012, and in the House of Lords on 13 December 2012, following which the regulations for amending the 1986 Act were signed by Lord Taylor of Holbeach, on behalf of the Government, on 18 December 2012. A version of the 1986 Act, which incorporates the changes made in 2012, is now available. 4
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The new EU Directive and the equivalent legislation in the EU Member States will be of little value, unless they can bring the production and use of genetically-altered animals under control and lead to a progressive and sustained reduction in laboratory animal use Along the way, I had attended a number of meetings of the Home Office Animal Welfare and Alternatives Group, had discussed various issues with the All Party Parliamentary Replacement Group (and its predecessor, the All Party Parliamentary FRAME Group), and I had been appreciative of the willingness of the Home Office officials to explain what was going on and to listen to what we had to say.
Thus, at the beginning of 2013, there was hope that sound progress would now be made toward the achievement of the three main aims of the new Directive as spelled out by Lord Taylor in the House of Lords debate, 5 namely, to rectify wide variations in the implementation of procedures among the Member States, to strengthen the protection of animals used in scientific procedures, and to promote the Three Rsstrategies that 'replace', 'reduce' and 'refine' the use of animals in scientific procedures.
Shocking Statistics
However, those of us who are genuinely committed to the Three Rs approach to the scientific and ethical problems inherent in subjecting living animals to potentially painful procedures, were to be sharply reminded of the stark reality of the daunting challenges ahead, when the Home Office published the Annual Statistics of Scientific Procedures on Living Animals -Great Britain 2012. 6 The total number of procedures started in 2012 increased to 4,110,028, 8% above the 2011 number (3, 792, 857) . This was 57% above the number of procedures reported in 2001, which had seen the lowest use of laboratory animals in Great Britain since 1955.
Mice were the most commonly-used species, accounting for 74% of the total number of procedures. The number of procedures involving mice increased by 14%, and there were also increases in the numbers of procedures involving goats (746%), Old World monkeys (29%), sheep (14%), and guinea-pigs (10%). There were decreases in the number of procedures involving pigs (22%), New World monkeys (19%), amphibians (14%), fish (11%), and rabbits (10%).
The overall increase was mainly due to a 22% (363,100) increase in the number of procedures involving genetically-altered (GA) animalsclassed as genetically-modified (GM) animals and animals with harmful genetic mutations (HM animals)to 1,976,881 procedures. For the first time, the number of procedures involving GM animals (1,908,519) exceeded that involving "normal" animals (1, 676, 528) .
The number of procedures involving GM animals in 2012 was 786% higher than the number in 1995, and the comparable number of procedures involving HM animals increased by 132%.
Altering the Genetic Make-up
Most of the GA procedures in 2012 involved mice -1,741,913 GM procedures and 441,610 HM procedures, in comparison with 875,298 procedures involving "normal" mice ( Table 1) .
A detailed discussion of GA animals is beyond the scope of this editorial, but mice are the preferred animals for this purpose, as they are small and easy to maintain in large numbers, and a great deal is known about their genetics.
GA mice are increasingly being used in a wide variety of approaches, aimed at increasing understanding of human diseases and developing ways in which they can be avoided or treated. Nevertheless, it is clear that their production, supply, maintenance and use is a vast and lucrative industry, that the methods involved are varied, sophisticated and rapidly evolving, but that the whole process can be highly wasteful of animal lives, and therefore of human and financial resources.
Genetic alteration can be achieved in a number of ways, including the induction of random changes in genes by using viruses, chemicals or radiation. For example, ethylnitrosourea (ENU) is used to induce point mutations, which tend to be deleterious. Male mice exposed to ENU are mated with untreated females, then the resultant progeny are screened for point mutations, some of which may be related to phenotypes of interest concerning particular body functions or diseases. Mice with spontaneous mutations can also be of interest.
Genetic alterations can also be produced by genetic engineering techniques, such as the deliberate insertion or deletion of DNA. Mice have about 25,000 genes, and there are global initiatives to create GM mice for every one of them. One approach is to knock out existing genes, in order to investigate their functions, by seeing how the loss of the activity of a particular gene affects morphology, biochemistry, physiology, behaviour and other observable features of the mice concerned.
By definition, transgenic mice contain additional foreign DNA in every cell, which requires that the DNA be introduced at a very early stage of development. Two main techniques are used. If the DNA is microinjected into the large, male-derived pronuclei of zygotes just after fertilisation, it tends to integrate into random positions in the genome, and some of the resultant transgenic cells may contribute to the germ line. The second technique is microinjection into embryonic stem (ES) cells which are then injected into blastocysts, which are transplanted into the uteruses of surrogate female mice. The ES cells colonise the host embryo, and will often contribute to the germ line. In both cases, some of the sperm eventually produced will carry the extra DNA, and, when they fertilise normal eggs, transgenic mice are produced, with the same foreign DNA in every cell. The numbers of procedures are taken from Tables 3.2 
and 3.3 of the 2012 Home Office Statistics. 8
Humanised mice carry functioning human genes, cells and tissues, which may result in the expression of the human protein/domain and the suppression of the mouse protein/domain. For example, immunodeficient mice given human immune system genes or cells can develop human immune responses.
One of the problems with all of this, as is pointed out in a useful NC3Rs fact sheet, 7 is that the generation of GA mice is slow and highly inefficient. Large numbers of animals are bred to produce a small number of animals of interest, and the rest are surplus to requirements. That is clear from Table 1 . As the NC3Rs fact sheet puts it, Female mice are used to provide either fertilised eggs or early-stage embryos as the raw material for genetic modification. These modified eggs or embryos are then implanted back into 'surrogate' female mice. A proportion of the offspring will carry the mutation. Once old enough, these will be bred to establish a colony of mice with a specific genetic modification to use for experimental purposes. For knock-out mice, both copies of the gene must be removed. This is a two phase process. Firstly, mice are produced with one copy of the gene removed (or modified). Then, in order to knock-out the second copy of the gene, it is necessary to breed together mice from the first phase. This step is inefficient in that only one in four of the offspring will have both copies knocked out, the other mice often being surplus to requirements. This can be further complicated by the fact that scientists also want the modification to be on a specific genetic background (or strain), and that also can require extensive breeding programmes, sometimes over six generations.
Regulating the Creation, Production and Use of GA Animals
The creation, production and use of GA animals raise many serious ethical and scientific questions, but my main concern in this comment is about how these procedures are regulated.
Directive 86/609/EEC and the Animals (Scientific Procedures) Act 1986 were already in force before the GA movement really took off, but those of us who are concerned about GA animals are surely entitled to expect that Directive 2010/63/EU and the corresponding national legislation in the Member States will apply no less to GA animals than to "normal" animals. How this will be achieved is not clear, although many difficulties are easily recog nisable.
There is no specific mention of GA animals in the main text of Directive 2010/63/EU, but preamble sections 3A, 3B and 3C of the amended Animals (Scientific Procedures) Act 1986 refer to situations where the modification of an animal's genes or the breeding of GA animals become regulated procedures. This is important, since the British Government has often come under pressure to exclude the breeding of GA animals from the counting of proce-dures. Happily, that pressure has been resisted, at least up to now.
The 4-page Annex VIII of the Directive, on the severity classification of procedures, is also of particular importance. It defines four severity categories (non-recovery, mild, moderate and severe) and gives examples of how different types of procedures should be assigned to them. In relation to GA animals, a mild procedure would involve breeding GA animals which is expected to result in a phenotype with mild effects or which are expected to have no clinically detectable adverse phenotype, and a moderate procedure would involve breeding of genetically altered animals which are expected to result in a phenotype with moderate effects; while a severe procedure would involve breeding animals with genetic disorders that are expected to experience severe and persistent impairment of general condition, e.g. Huntington's disease, muscular dystrophy and chronic relapsing neuritis models.
Many of the other criteria would, of course apply equally to GA and "normal" animals.
Given that, in the future, it is likely that most of the animals to which the Directive applies will be GA animals, it will be important that reports from the Commission and from the Member States deal specifically with how the Directive is being applied to them.
The regulation of the genetic alteration of animals is not straightforward. Much of the work involved is not targeted to specific genes or diseases, but is more like a shotgun approach -"Let's induce mutations or knock-out genes, then see what happens, and whether it has any significant biomedical relevance or could be useful to us or somebody else".
It is argued that the overall approach could sometimes be beneficial, but the evaluation would essentially be retrospective. Similarly, it would be impossible to predict, in a meaningful way, the pain, suffering or distress caused to the GA animals. Many of the effects would be lethal, while others would undoubtedly result in severe harm.
It can also be argued that the genetic alteration and/or breeding of mice with diseases related to human diseases, raises scientific and ethical questions. These relate, not only to benefit versus harm, but also to relevance. Do we know enough about the human diseases to make sensible judgements about whether or not the animal models are relevant?
Because of uncertainty over both benefit and harm in particular experiments, it is not possible to convincingly apply any benefit-harm evaluation at the beginning of a project. At the very least, there should be an insistence on a rigorous retrospective assessment.
The question to be faced, is how this all fits with statements about the intrinsic value of animals, the need for an upper limit of pain, suffering and distress, and the essential need to ensure that each use of an animal is carefully evaluated as to the scientific or education validity, usefulness and relevance of the expected result of that use. Note that the preamble to the Directive says this is essential both on moral and scientific grounds.
Another question relates to what limits will be/should be placed on the genetic alteration of animals, particularly in the humanisation of animals and the creation of human-animal hybrids.
Concluding Comments
Despite the hope engendered by Directive 2010/63/ EU, there is a danger that its specific requirements will have little effect on the suffering endured by around 50% of the animals used for scientific purposes (given that nearly 2 million of the overall total of 4.1 million procedures started in 2012 in the UK alone involved GA animals). If that turns out to be the case, the credibility and integrity of this major step in European Union legislation will be lost.
One encouraging point is that the NC3Rs are very concerned about the welfare of GA animals, and has already supported 19 projects costing £4.5 million, aimed at replacing and reducing the use of GA mice, and refinement of the procedures applied to the animals that continue to be required. 7 Finally, however, it must be admitted that there is one overriding issuehow much do mice really matter? If the answer is, "Not very much", we shouldn't pretend that laws which refer to their intrinsic value, etc. have any merit. If the answer is, "A great deal", we should insist that they are given the genuine and effective protection that they deserve, and which the Directive and the laws of the Member States require. 
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